Phaseline

Companies › AskBio France, SAS, a subsidiary of AskBio

AskBio France, SAS, a subsidiary of AskBio: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Apr 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AB-1001 (AAVrh10.CAG.hCYP46A1)
AAV-mediated gene delivery of human cholesterol 24-hydroxylase (CYP46A1)
CYP46A1Phase 1Huntington DiseaseApr 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05541627AB-1001 (AAVrh10.CAG.hCYP46A1)Phase 1Huntington DiseaseNeurologyApr 2028

Targets

CYP46A1 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.